Search
PAVmed Inc
PAVMAdd to Watchlist
5.710USD
-0.540-8.57%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.39MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-8.57%
5 Days
+13.07%
1 Month
+4.77%
6 Months
-22.10%
Year to Date
-13.80%
1 Year
+856.29%
Key Figures
6.300Open
6.300High
25.61KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
3.33%Turnover Ratio
6.300Prev. Close
5.710Low
128.00KTurnover
0.14P/E Static
0.52P/B
0.00%Div Yield TTM
-45.10%ROA
28.44052wk High
1.66Volume Ratio
31.97MNet Profit
768.45KShares
-211.5445EPS TTM
0.60Beta
-97.72%ROE
6.00052wk Low
9.37%Amplitude
-340.91%Gross Margin
4.39MMarket Cap
2.67Reward/Risk
5.83%Risk Rate
TradingKey Stock Score of PAVmed Inc
Currency: USD Updated: 2026-07-02Key Insights
PAVmed Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 84 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 36.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PAVmed Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
PAVmed Inc Highlights
StrengthsRisks
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Growing
The company is in a growing phase, with the latest annual income totaling USD 71.00K.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -0.03, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 736.95K shares, increasing 47.24% quarter-over-quarter.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
36.000
Target Price
+471.43%
Upside Space
PAVmed Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
PAVmed Inc Info
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.
Ticker SymbolPAVM
CompanyPAVmed Inc
CEOAklog (Lishan)
Websitehttps://pavmed.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of PAVmed Inc (PAVM)?
The current price of PAVmed Inc (PAVM) is 5.71.
What is the symbol of PAVmed Inc?
The ticker symbol of PAVmed Inc is PAVM.
What is the 52-week high of PAVmed Inc?
The 52-week high of PAVmed Inc is 28.44.
What is the 52-week low of PAVmed Inc?
The 52-week low of PAVmed Inc is 6.00.
What is the market capitalization of PAVmed Inc?
The market capitalization of PAVmed Inc is 4.39M.
Is PAVmed Inc (PAVM) currently rated as Buy, Hold, or Sell?
According to analysts, PAVmed Inc (PAVM) has an overall rating of Buy, with a price target of 36.00.
What is the Earnings Per Share (EPS TTM) of PAVmed Inc (PAVM)?
The Earnings Per Share (EPS TTM) of PAVmed Inc (PAVM) is -168.87.